| Host |
Rabbit |
| Klon |
EP3 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Diva modified Citrate pH 6.2 |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane |
HER2 (c-erbB-2)
|
Biocare Medical |
EP3 |
6 ml |
Ready-to-use |
RUO |
PME342AA |
-
|
| Host |
Rabbit |
| Klon |
EP3 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Zytomed Systems GmbH |
EP3 |
6 ml |
Ready-to-use |
RUO |
RBG067 |
-
|
| Host |
Rabbit |
| Klon |
EP3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Zytomed Systems GmbH |
EP3 |
1 ml |
Concentrate |
RUO |
RBK067 |
-
|
| Host |
Rabbit |
| Klon |
EP3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Zytomed Systems GmbH |
EP3 |
0.5 ml |
Concentrate |
RUO |
RBK067-05 |
-
|
| Host |
Rabbit |
| Klon |
SP3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Diagnostic Biosystems |
SP3 |
1 ml |
Concentrate |
CE/IVD |
RMAB008 |
-
|
| Host |
Rabbit |
| Klon |
SP3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Diagnostic Biosystems |
SP3 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB008-01 |
-
|
| Host |
Rabbit |
| Klon |
SP3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Diagnostic Biosystems |
SP3 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB008-05 |
-
|
| Host |
Rabbit |
| Klon |
SP3 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Diagnostic Biosystems |
SP3 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD008 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrat |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP006 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrat |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP006-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrat |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell Membrane |
HER2 (c-erbB-2)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP006-05 |
-
|
| Host |
Rabbit |
| Klon |
SP101 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant protein encoding extracellular domain of human c-erbB-2 |
| Lokalisation |
Cell Membrane |
HER2/c-erbB2
|
Zytomed Systems GmbH |
SP101 |
0.5 ml |
Concentrate |
RUO |
508-4012 |
-
|
| Host |
Rabbit |
| Klon |
SP101 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant protein encoding extracellular domain of human c-erbB-2 |
| Lokalisation |
Cell Membrane |
HER2/c-erbB2
|
Zytomed Systems GmbH |
SP101 |
1 ml |
Concentrate |
RUO |
508-4014 |
-
|
| Host |
Rabbit |
| Klon |
SP71 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Small Intestine |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to internal region of human c-erbB3 |
| Lokalisation |
Cell Membrane |
HER3 (c-erbB-3)
|
Zytomed Systems GmbH |
SP71 |
1 ml |
Concentrate |
RUO |
508-3714 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
IF |
| Isotyp |
Rabbit IgG |
| Verdünnung |
HSV strain F (human) |
Herpes Simplex Virus I, II (HSV I, II)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
608-0115 |
-
|
| Host |
Mouse |
| Klon |
0195 |
| Format |
Purified |
| Methode |
EL, IF |
| Isotyp |
Mouse IgG1 |
Herpes Simplex Virus I, II, Glycoprotein D (HSV I, II)
|
Zytomed Systems GmbH |
0195 |
100 µg |
Purified |
RUO |
608-0119 |
-
|
| Host |
Rabbit |
| Klon |
ZR106 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Kaposi’s sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant protein corresponding to the latent nuclear antigen 1 molecule of HHV8 |
| Lokalisation |
Nucleus |
HHV-8
|
Zeta Corporation |
ZR106 |
1ml |
Concentrate |
CE/IVD |
Z2531RL |
-
|
| Host |
Rabbit |
| Klon |
ZR106 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Kaposi’s sarcoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant protein corresponding to the latent nuclear antigen 1 molecule of HHV8 |
| Lokalisation |
Nucleus |
HHV-8
|
Zeta Corporation |
ZR106 |
7 ml |
Ready-to-use |
CE/IVD |
Z2531RP |
-
|
| Host |
Rabbit |
| Klon |
ZR106 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Kaposi’s sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant protein corresponding to the latent nuclear antigen 1 molecule of HHV8 |
| Lokalisation |
Nucleus |
HHV-8
|
Zeta Corporation |
ZR106 |
0.5 ml |
Concentrate |
CE/IVD |
Z2531RS |
-
|
| Host |
Rabbit |
| Klon |
ZR106 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Kaposi’s sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant protein corresponding to the latent nuclear antigen 1 molecule of HHV8 |
| Lokalisation |
Nucleus |
HHV-8
|
Zeta Corporation |
ZR106 |
0.1 ml |
Concentrate |
CE/IVD |
Z2531RT |
-
|
| Host |
Rat |
| Klon |
LN53 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Infected Tissue |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG3 |
| Lokalisation |
Nucleus |
HHV-8 (Human Herpes Virus)
|
Diagnostic Biosystems |
LN53 |
1 ml |
Concentrate |
CE/IVD |
MOB395 |
-
|
| Host |
Rat |
| Klon |
LN53 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Infected Tissue |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG3 |
| Lokalisation |
Nucleus |
HHV-8 (Human Herpes Virus)
|
Diagnostic Biosystems |
LN53 |
0.1 ml |
Concentrate |
CE/IVD |
MOB395-01 |
-
|
| Host |
Rat |
| Klon |
LN53 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Infected Tissue |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG3 |
| Lokalisation |
Nucleus |
HHV-8 (Human Herpes Virus)
|
Diagnostic Biosystems |
LN53 |
0.5 ml |
Concentrate |
CE/IVD |
MOB395-05 |
-
|
| Host |
Rat |
| Klon |
LN53 |
| Format |
ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Infected Tissue |
| Verdünnung |
--- |
| Isotyp |
IgG3 |
| Lokalisation |
Nucleus |
HHV-8 (Human Herpes Virus)
|
Diagnostic Biosystems |
LN53 |
6 ml |
ready-to-use |
CE/IVD |
PDM395 |
-
|
| Host |
Rabbit |
| Klon |
EP1215Y |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
HIF-1 alpha
|
Biocare Medical |
EP1215Y |
0.1 ml |
Concentrate |
CE/IVD |
CME349A |
-
|
| Host |
Rabbit |
| Klon |
EP1215Y |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast cancer |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
HIF-1 alpha
|
Biocare Medical |
EP1215Y |
0.5 ml |
Concentrate |
CE/IVD |
CME349B |
-
|
| Host |
Mouse |
| Klon |
AD1.1.10 |
| Format |
Purified |
| Methode |
F, EL, WB, IP |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
PAX6 transcription factor linked to histidine tag |
His-Tag Epitope Tag (6-Histidine)
|
Zytomed Systems GmbH |
AD1.1.10 |
1 mg |
Purified |
RUO |
608-0143 |
-
|
| Host |
Mouse |
| Klon |
AD1.1.10 |
| Format |
Purified |
| Methode |
F, EL, IP |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
PAX6 transcription factor linked to histidine tag |
Histidine Tag
|
Zytomed Systems GmbH |
AD1.1.10 |
100 µg |
Purified |
RUO |
608-0144 |
-
|
| Host |
Mouse |
| Klon |
BB7.2 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG2b |
| Verdünnung |
Papain solubilized HLA-A2 |
HLA-A2
|
Zytomed Systems GmbH |
BB7.2 |
200 µg |
Purified |
RUO |
608-0218 |
-
|
| Host |
Mouse |
| Klon |
W6/32 |
| Format |
Purified |
| Methode |
F, EL, IP, FL, IHC(F) |
| Positivkontrolle |
Tonsil |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Purified human tonsil lymphocyte membranes |
HLA Class 1 Antigen ABC
|
Zytomed Systems GmbH |
W6/32 |
200 µg |
Purified |
RUO |
608-0192 |
-
|
| Host |
Mouse |
| Klon |
WR18 |
| Format |
Purified |
| Methode |
FL, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Human HLA Classe II (DP, DQ, DR) |
HLA Class 2 Antigen DR, DP, DQ
|
Zytomed Systems GmbH |
WR18 |
200 µg |
Purified |
RUO |
608-0209 |
-
|
| Host |
Mouse |
| Klon |
TAL 1B5 |
| Format |
concentrated |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
0.1 ml |
concentrated |
CE/IVD |
ACI3273A |
-
|
| Host |
Mouse |
| Klon |
TAL 1B5 |
| Format |
concentrated |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
1 ml |
concentrated |
CE/IVD |
ACI3273C |
-
|
| Host |
Mouse |
| Klon |
TAL 1B5 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3273G7 |
-
|
| Host |
Mouse |
| Klon |
TAL 1B5 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
6 ml |
Ready-to-use |
CE/IVD |
API3273 |
-
|
| Host |
Mouse |
| Klon |
TAL 1B5 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
cell membrane |
HLA-DR
|
Biocare Medical |
TAL 1B5 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3273G |
-
|
| Host |
Mouse |
| Klon |
CR3/43 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
1 ml |
Concentrate |
RUO |
MOB069R |
-
|
| Host |
Mouse |
| Klon |
CR3/43 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
0.1 ml |
Concentrate |
RUO |
MOB069R-01 |
-
|
| Host |
Mouse |
| Klon |
CR3/43 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
0.5 ml |
Concentrate |
RUO |
MOB069R-05 |
-
|
| Host |
Mouse |
| Klon |
CR3/43 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
HLA-DR (β chain of DP, DQ & DR)
|
Diagnostic Biosystems |
CR3/43 |
6 ml |
Ready-to-use |
RUO |
PDM082 |
-
|
| Host |
Mouse |
| Klon |
MEM-G/1 |
| Format |
Purified |
| Methode |
WB, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Human Placenta |
| Isotyp |
Mouse IgG1 |
HLA-G
|
Zytomed Systems GmbH |
MEM-G/1 |
200 µg |
Purified |
RUO |
608-0223 |
-
|
| Host |
Mouse |
| Klon |
HMB45+M2-7C10+M2-9E3+T311 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse Ig |
| Lokalisation |
Cytoplasm |
HMB45 + MART-1 + Tyrosinase
|
Biocare Medical |
HMB45+M2-7C10+M2-9E3+T311 |
6 ml |
Ready-to-use |
CE/IVD |
VP165 |
-
|
| Host |
Mouse |
| Klon |
CAMVR-1 & C1P5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HPV infected cells of tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a/k + IgG1/k |
| Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
| Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
1ml |
Concentrate |
RUO |
Z2657ML-R |
-
|
| Host |
Mouse |
| Klon |
CAMVR-1 & C1P5 |
| Format |
r-t-u |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HPV infected cells of tissue |
| Verdünnung |
- |
| Isotyp |
IgG2a/k + IgG1/k |
| Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
| Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
7ml |
r-t-u |
RUO |
Z2657MP-R |
-
|
| Host |
Mouse |
| Klon |
CAMVR-1 & C1P5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HPV infected cells of tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a/k + IgG1/k |
| Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
| Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
0.5 ml |
Concentrate |
RUO |
Z2657MS-R |
-
|
| Host |
Mouse |
| Klon |
CAMVR-1 & C1P5 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
HPV infected cells of tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a/k + IgG1/k |
| Verdünnung |
HPV16 major capsid protein L1 and recombinant full-length protein corresponding to HPV16 E6 & HPV18 E6 |
| Lokalisation |
Nuclei of infected cells |
HPV
|
Zeta Corporation |
CAMVR-1 & C1P5 |
0.1 ml |
Concentrate |
RUO |
Z2657MT-R |
-
|
| Host |
Mouse |
| Klon |
CAMVIR-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
HPV Infected Cervix Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2a |
| Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
1 ml |
Concentrate |
CE/IVD |
MOB394 |
-
|
| Host |
Mouse |
| Klon |
CAMVIR-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
HPV Infected Cervix Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2a |
| Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB394-01 |
-
|
| Host |
Mouse |
| Klon |
CAMVIR-1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
HPV Infected Cervix Tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2a |
| Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB394-05 |
-
|
| Host |
Mouse |
| Klon |
CAMVIR-1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
HPV Infected Cervix Tissue |
| Verdünnung |
- |
| Isotyp |
IgG2a |
| Lokalisation |
Nucleus |
HPV 16, L1 (Papillomavirus Type 16)
|
Diagnostic Biosystems |
CAMVIR-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM166 |
-
|